Please ensure Javascript is enabled for purposes of website accessibility

Why Corindus Vascular Robotics Is Soaring Today

By Brian Feroldi - Updated May 8, 2019 at 11:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares jump even though its first-quarter results fell short of Wall Street's estimates. What can explain the optimism?

What happened

In response to reporting of first-quarter results, shares of Corindus Vascular Robotics (CVRS), a medical device company focused on vascular disease, rose 14% as of 10:45 a.m. EDT on Wednesday.

So what

Here are the key financial numbers from the quarter:

  • Revenue doubled to $3 million. That was slightly behind the $3.11 million that Wall Street was expecting.
  • Gross profit improved just 50% to $0.6 million, which is a slower rate of growth than revenue.
  • Net loss declined slightly to $9.7 million, or $0.05 per share. That was worse than the $0.04 net loss that was expected.
  • Cash balance at quarter-end was $37.8 million.
  • The company raised $19.8 million during the quarter in a private-placement transaction.
Money raining down on businessman with an umbrella.

Image source: Getty Images.

The company also shared some nonfinancial updates with investors:

  • Corindus received 11 purchase orders for its CorPath GRX Systems. That represents growth of 267% when compared to the year-ago period, albeit off of a very small base.
  • The company received European approval for a neurovascular indication, which enables it to sell neurovascular robots in 33 countries.
  • Its first purchase order was received in Italy.

Traders appear to be looking past the worse-than-expected quarterly numbers and are focusing their attention on the strong growth in purchase orders.

Now what

Corindus' purchase order growth shows that it continues to make progress with its commercialization efforts. However, the company's financial statements continue to give me pause. The company's bank balance of $37.8 million won't last long if it continues to burn about $10 million per quarter, so investors might want to brace themselves for another capital raise in the not-too-distant future.

I continue to believe that Corindus is an intriguing company, but I would like to see a lot more business traction before I call the stock a buy. Until that happens, I'm content to focus my time and attention on other medical device makers.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Corindus Vascular Robotics, Inc. Stock Quote
Corindus Vascular Robotics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.